Skip to Content
Merck
CN

Key Documents

View All Documentation

GE17-1440-02

Ficoll® Paque Plus

liquid, sterile (endotoxins < 0.12 EU/mL), density: 1.077 g/mL, pack of 6 × 100 mL

Synonym(s):

Ficoll density gradient medium, cell culture media, 17-1440-02, cell purification media, cell storage media, density gradient media, lymphocyte separation medium, mononuclear cell isolation

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.25
UNSPSC Code:
41105330
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

sterility

sterile (endotoxins < 0.12 EU/mL)

form

liquid

shelf life

3 yr

packaging

pack of 6 × 100 mL

manufacturer/tradename

Cytiva 17-1440-02

storage condition

protect from light ()

dilution

(purification of mononuclear cells from human peripheral blood)

color

Colorless to slightly yellow

pH range

5.5-7.5

density

1.077 g/mL

storage temp.

2-30°C

General description

Ficoll-Paque Plus is a recognized standard in laboratories worldwide for the isolation of human lymphocytes for in vitro studies.

Ficoll-Paque PLUS is a ready to use, sterile medium for isolation of lymphocytes in high yield from peripheral blood using a simple and rapid centrifugation procedure. It maintains the viability and a representative distribution of B and T lymphocytes.

Application

For in vitro isolation of lymphocytes from human peripheral blood.

Features and Benefits

  • Ready to use sterile medium for isolation of human lymphocytes in high yield from peripheral blood.
  • Maintains viability and representative distribution of B and T lymphocytes.
  • Low levels of endotoxin (< 0.12 EU/mL).

Preparation Note

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
Store at 4 to 30 °C ()

Analysis Note

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Legal Information

Ficoll is a registered trademark of Cytiva

Still not finding the right product?

Explore all of our products under Ficoll® Paque Plus

pictograms

Flame
GHS02

signalword

Danger

hcodes

H225

Hazard Classifications

Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk

WGK 3

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Protocols

Ficoll® 400 for Gradient Centrifugation

Ficoll 400® is a non-ionic polymer with high hydrophilicity and water solubility, suitable for various biological applications.

用于梯度离心的Ficoll® 400

Ficoll 400®是由蔗糖和环氧氯丙烷共聚而成的一种高度分支化的聚合物。Ficoll 400®是完全非离子性的。由于其含有丰富的羟基，Ficoll 400®具有很强的亲水性和水溶性。

Articles

Properties of Mononuclear Cells Isolated by the Ficoll-Paque Method

The effects of the mononuclear cell separation method described by Bøyum procedure are noted below, since research situations may arise in which they are significant.

Amalesh Nanda et al.
Annals of laboratory medicine, 40(5), 390-397 (2020-04-21)
The effect of the interplay among inflammation, angiogenesis, extracellular matrix (ECM) degradation, and oxidative stress (OS) on the pathogenesis of endometriosis remains unclear. Previously, we demonstrated the role of OS in endometriosis. Here, we performed a comprehensive investigation of several
Mehdi Hassanpour et al.
Stem cell research & therapy, 11(1), 139-139 (2020-03-29)
To date, many attempts are employed to increase the regenerative potential of stem cells. In this study, we evaluated the hypothesis of whether an autophagy modulation could alter differentiation potency of CD146+ cells into mature pericyte, endothelial, and cardiomyocyte lineage.
Matthew A Lakins et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(15), 4154-4167 (2020-04-30)
With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for patients with relapsing or refractory cancer. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1, to induce T-cell activation
View All Related Papers

Global Trade Item Number

SKUGTIN
GE17-1440-0204061837621444